[go: up one dir, main page]

BRPI0417334A - proteìna nmb0928 e uso da mesma em formulações farmacêuticas - Google Patents

proteìna nmb0928 e uso da mesma em formulações farmacêuticas

Info

Publication number
BRPI0417334A
BRPI0417334A BRPI0417334-1A BRPI0417334A BRPI0417334A BR PI0417334 A BRPI0417334 A BR PI0417334A BR PI0417334 A BRPI0417334 A BR PI0417334A BR PI0417334 A BRPI0417334 A BR PI0417334A
Authority
BR
Brazil
Prior art keywords
formulations
nmb0928
protein
diseases
nmb0928 protein
Prior art date
Application number
BRPI0417334-1A
Other languages
English (en)
Inventor
Rolando Pajon Feyt
Gerardo Enrique Guillem Nieto
Gretel Sardi As Garcia
Lazaro Hiram Betancourt Nu Ez
Lila Rosa Castellanos Serra
Yasser Perera Negrin
Darien Garcia Diaz
Olivia Niebla Perez
Evelin Caballero Menendez
Sonia Gonzalez Blanco
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of BRPI0417334A publication Critical patent/BRPI0417334A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626—Diabody or triabody

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

"PROTEìNA NMB0928 E USO DA MESMA EM FORMULAçõES FARMACêUTICAS". A presente invenção refere-se ao uso de um novo antígeno para vacina aplicado como uma medida preventiva ou terapêutica contra doenças em geral, sendo essas doenças de origem bacteriana, viral, câncer correlato, ou outras origens. O objetivo técnico que esta invenção prossegue é o desenvolvimento de formulações com a capacidade de aumentar o espectro protetor de vacinas existentes e, portanto, expandindo-o contra diferentes patógenos. A fim de atingir esse objetivo a proteína NMB0928 foi isolada e identificada como um componente de preparações de membranas externas de Nelsseria meningitidis capaz de induzir atividade bactericida. Adicionalmente, o gene que codifica a proteína NMB0928 foi clonado e expresso, e o polipeptídeo foi purificado e sua imunogenicidade avaliada em modelos animais. Os dados de seqüência de genes homólogos mostraram, devido ao alto grau de conservação, seu alto valor como um antígeno alvo de uma resposta reativa de forma cruzada quando ele é apresentado por vias diferentes. Formulações resultantes desta invenção são de uso na indústria farmacêutica como formulações de vacina para uso humano.
BRPI0417334-1A 2003-12-03 2004-12-02 proteìna nmb0928 e uso da mesma em formulações farmacêuticas BRPI0417334A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CU2002008620030286A CU23236A1 (es) 2003-12-03 2003-12-03 PROTEINA NMB0928 Y SU USO EN FORMULACIONES FARMACéUTICAS P
PCT/CU2004/000016 WO2005054282A1 (es) 2003-12-03 2004-12-02 Proteína nmb0928 y su uso en formulaciones farmaceuticas

Publications (1)

Publication Number Publication Date
BRPI0417334A true BRPI0417334A (pt) 2007-03-27

Family

ID=40091627

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0417334-1A BRPI0417334A (pt) 2003-12-03 2004-12-02 proteìna nmb0928 e uso da mesma em formulações farmacêuticas

Country Status (16)

Country Link
US (1) US20070128230A1 (pt)
EP (1) EP1693379B1 (pt)
KR (1) KR20060124625A (pt)
CN (1) CN100549027C (pt)
AR (1) AR046937A1 (pt)
AT (1) ATE456573T1 (pt)
AU (1) AU2004294377A1 (pt)
BR (1) BRPI0417334A (pt)
CA (1) CA2547537A1 (pt)
CU (1) CU23236A1 (pt)
DE (1) DE602004025377D1 (pt)
NO (1) NO20063017L (pt)
NZ (1) NZ547521A (pt)
RU (1) RU2335505C2 (pt)
WO (1) WO2005054282A1 (pt)
ZA (1) ZA200604492B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU23549A1 (es) * 2005-12-29 2010-07-20 Ct Ingenieria Genetica Biotech Composiciones farmacéuticas que contienen la proteína nma0939
CU23575A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0606
CU23572A1 (es) * 2006-03-31 2010-09-30 Ct Ingenieria Genetica Biotech Composición farmacéutica que comprende la proteína nmb0938
EP4309670A3 (en) 2016-09-02 2024-07-17 Sanofi Pasteur, Inc. Neisseria meningitidis vaccine

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4219821A1 (de) * 1992-06-17 1993-12-23 Boehringer Mannheim Gmbh Spezifischer Nachweis von Neisseria Gonorrhoeae
CU22559A1 (es) * 1996-01-17 1999-05-03 Ct Ingenieria Genetica Biotech Sistema de expresión de antígenos heterologos en e. coli como proteínas de fusión
BR9910089A (pt) * 1998-05-01 2004-06-08 Chiron Corp Composições e antìgenos de neisseria meningitidis
GB9911683D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic peptides
GB9911692D0 (en) * 1999-05-19 1999-07-21 Chiron Spa Antigenic combinations
EP2275553B1 (en) * 1999-10-29 2015-05-13 Novartis Vaccines and Diagnostics S.r.l. Neisserial antigenic peptides
GB9928196D0 (en) * 1999-11-29 2000-01-26 Chiron Spa Combinations of B, C and other antigens

Also Published As

Publication number Publication date
EP1693379B1 (en) 2010-01-27
AR046937A1 (es) 2006-01-04
RU2006123414A (ru) 2008-01-10
EP1693379A1 (en) 2006-08-23
CA2547537A1 (en) 2005-06-16
CN1890261A (zh) 2007-01-03
CU23236A1 (es) 2007-09-26
WO2005054282A1 (es) 2005-06-16
US20070128230A1 (en) 2007-06-07
NO20063017L (no) 2006-09-01
ATE456573T1 (de) 2010-02-15
RU2335505C2 (ru) 2008-10-10
KR20060124625A (ko) 2006-12-05
NZ547521A (en) 2009-07-31
ZA200604492B (en) 2007-05-30
CN100549027C (zh) 2009-10-14
AU2004294377A1 (en) 2005-06-16
DE602004025377D1 (de) 2010-03-18

Similar Documents

Publication Publication Date Title
ES2670859T3 (es) Secuencias peptídicas y composiciones de Anopheles gambiae
BR112018076633A2 (pt) mutante recombinante de asfv-g (isolado georgia 2007 do vírus de febre suína africana), cdna mutante, composição de vacina, método para a proteção de suínos contra o isolado georgia 2007 do vírus da febre suína - (asfv-g), método para diferenciar um mamífero vacinado com uma vacina viva atenuada asfv-g ¿9gl/¿uk
US10729636B2 (en) Compositions comprising peptide WKDEAGKPLVK
JP6632974B2 (ja) フェノール可溶性モジュリン、δ毒素、スーパー抗原に由来するトキソイドペプチド、およびその融合物
ES2926543T3 (es) Atenuación de la virulencia bacteriana mediante la atenuación del transporte de folato bacteriano
CA3233697A1 (en) Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
UA113496C2 (xx) Вектор і спосіб підвищення стійкості до інфекції, що викликається campylobacter
McManus A vaccine against Asian schistosomiasis: the story unfolds
Hashemzehi et al. Cloning and expression of nlpA gene as DNA vaccine candidate against Acinetobacter baumannii
Li et al. A recombinant multi-epitope peptide vaccine based on MOMP and CPSIT_p6 protein protects against Chlamydia psittaci lung infection
TW201643180A (zh) 鮑氏不動桿菌（Ａｃｉｎｅｔｏｂａｃｔｅｒ ｂａｕｍａｎｎｉｉ）多胜肽抗原及其抗體以及編碼該抗原之核酸
Nooreh et al. Protective and immunostimulatory effects of in-feed preparations of an anticoccidial, a probiotic, a vitamin-selenium complex, and Ferulago angulata extract in broiler chickens infected with Eimeria species
Khanifar et al. Prevention of EHEC infection by chitosan nano-structure coupled with synthetic recombinant antigen
Liu et al. Identification and analysis of a Sciaenops ocellatus ISG15 homologue that is involved in host immune defense against bacterial infection
BRPI0417334A (pt) proteìna nmb0928 e uso da mesma em formulações farmacêuticas
BRPI0818957B8 (pt) gene isolado, vetor de expressão, célula hospedeira geneticamente modificada e método para preparação de uma macromolécula imunogênica
BRPI0417309A (pt) proteìna nmb1125 e seu uso em formulações farmacêuticas
JP2008517595A (ja) ワクチンと核酸
JP2012509664A (ja) スタフィロコッカス・アウレウス（ｓｔａｐｈｙｌｏｃｏｃｃｕｓａｕｒｅｕｓ）に対する防御免疫応答を誘導するポリペプチド
Nuñez-Ortiz et al. Immunostimulant properties of full-length and truncated Marinobacter algicola flagellins, and their effects against viral hemorrhagic septicemia virus (VHSV) in trout
BR112014007491A2 (pt) sequências de aminoácidos para o controle de patógenos
Siles-Lucas et al. The Schistosoma bovis Sb14-3-3ζ recombinant protein cross-protects against Schistosoma mansoni in BALB/c mice
BR0208980A (pt) Vacinas incluindo ifn do tipo i como um adjuvante e processos relacionados a esses
Hang et al. Molecular characterization and tissue localization of glutathione S-transferase from adult Ancylostoma ceylanicum
WO2012021229A1 (en) Staphylococcus aureus surface protein sa1789 and protective vaccine based thereon

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADE(S)

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.